PE20021083A1 - Moduladores de los receptores estrogenos - Google Patents
Moduladores de los receptores estrogenosInfo
- Publication number
- PE20021083A1 PE20021083A1 PE2002000308A PE2002000308A PE20021083A1 PE 20021083 A1 PE20021083 A1 PE 20021083A1 PE 2002000308 A PE2002000308 A PE 2002000308A PE 2002000308 A PE2002000308 A PE 2002000308A PE 20021083 A1 PE20021083 A1 PE 20021083A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycloalkyl
- alkenyl
- modulators
- acetophenone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/08—Six-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA I DONDE R1 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, OR6, ENTRE OTROS; R2 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, ENTRE OTROS; R3 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, ENTRE OTROS; R4 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, ENTRE OTROS; R5 ES ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ENTRE OTROS; X E Y SON O, S, SULFOXIDO, SULFONA; R6 ES H, ALQUILO C1-C5, BENCILO, METOXIMETILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-TIOFENO-4-METOXI-ACETOFENONA, 2-TIOFENO-4-HIDROXI-ACETOFENONA, 2-TIOFENO-4-METOXI-ACETOFENONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON MODULADORES DE LOS RECEPTORES ESTROGENOS Y SON UTILES PARA EL TRATAMIENTO DE OSTEOPOROSIS, DEGENERACION DE CARTILAGO, ENDOMETRIOSIS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24158200P | 2000-10-19 | 2000-10-19 | |
| PCT/US2001/042735 WO2002032377A2 (en) | 2000-10-19 | 2001-10-15 | Estrogen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20021083A1 true PE20021083A1 (es) | 2002-12-16 |
Family
ID=22911282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000308A PE20021083A1 (es) | 2000-10-19 | 2002-04-15 | Moduladores de los receptores estrogenos |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1333827A2 (es) |
| JP (1) | JP2004511502A (es) |
| KR (1) | KR20030042020A (es) |
| CN (1) | CN1469743A (es) |
| AU (2) | AU3238102A (es) |
| BG (1) | BG107676A (es) |
| BR (1) | BR0114689A (es) |
| CA (1) | CA2424729A1 (es) |
| EA (1) | EA200300474A1 (es) |
| EC (1) | ECSP034558A (es) |
| EE (1) | EE200300153A (es) |
| HU (1) | HUP0303563A2 (es) |
| IL (1) | IL154984A0 (es) |
| IS (1) | IS6761A (es) |
| MX (1) | MXPA03003485A (es) |
| NO (1) | NO20031737L (es) |
| PE (1) | PE20021083A1 (es) |
| PL (1) | PL361053A1 (es) |
| SK (1) | SK4772003A3 (es) |
| WO (1) | WO2002032377A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225132A1 (en) * | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
| WO2003091239A1 (en) | 2002-04-24 | 2003-11-06 | Merck & Co., Inc. | Estrogen receptor modulators |
| AU2003292625B2 (en) * | 2002-12-26 | 2008-07-24 | Eisai R & D Management Co., Ltd. | Selective estrogen receptor modulators |
| AU2006275514B2 (en) | 2005-07-29 | 2012-04-05 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| CA2627139A1 (en) * | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
| CA2676984C (en) | 2007-02-01 | 2015-03-17 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| ES2542835T3 (es) | 2009-01-08 | 2015-08-12 | Resverlogix Corporation | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
| JP5795304B2 (ja) | 2009-03-18 | 2015-10-14 | レスバーロジックス コーポレイション | 新規抗炎症剤 |
| KR101892987B1 (ko) | 2009-04-22 | 2018-08-30 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| KR101698238B1 (ko) | 2010-06-10 | 2017-01-19 | 세라곤 파마슈티컬스, 인크. | 에스트로겐 수용체 조정제 및 이의 용도 |
| WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| CA2851996C (en) | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
| SG11201403002RA (en) | 2011-12-14 | 2014-07-30 | Seragon Pharmaceuticals Inc | Fluorinated estrogen receptor modulators and uses thereof |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| EP2935253B1 (en) | 2012-12-21 | 2018-08-01 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| CA2977308A1 (en) | 2015-03-13 | 2016-09-22 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
-
2001
- 2001-10-15 EA EA200300474A patent/EA200300474A1/ru unknown
- 2001-10-15 KR KR10-2003-7005518A patent/KR20030042020A/ko not_active Application Discontinuation
- 2001-10-15 BR BR0114689-0A patent/BR0114689A/pt not_active Application Discontinuation
- 2001-10-15 CN CNA018176720A patent/CN1469743A/zh active Pending
- 2001-10-15 SK SK477-2003A patent/SK4772003A3/sk unknown
- 2001-10-15 AU AU3238102A patent/AU3238102A/xx active Pending
- 2001-10-15 MX MXPA03003485A patent/MXPA03003485A/es unknown
- 2001-10-15 EP EP01987654A patent/EP1333827A2/en not_active Withdrawn
- 2001-10-15 HU HU0303563A patent/HUP0303563A2/hu unknown
- 2001-10-15 PL PL01361053A patent/PL361053A1/xx not_active Application Discontinuation
- 2001-10-15 CA CA002424729A patent/CA2424729A1/en not_active Abandoned
- 2001-10-15 JP JP2002535616A patent/JP2004511502A/ja not_active Withdrawn
- 2001-10-15 WO PCT/US2001/042735 patent/WO2002032377A2/en not_active Application Discontinuation
- 2001-10-15 EE EEP200300153A patent/EE200300153A/xx unknown
- 2001-10-15 IL IL15498401A patent/IL154984A0/xx unknown
- 2001-10-15 AU AU2002232381A patent/AU2002232381B2/en not_active Ceased
-
2002
- 2002-04-15 PE PE2002000308A patent/PE20021083A1/es not_active Application Discontinuation
-
2003
- 2003-03-26 BG BG107676A patent/BG107676A/bg unknown
- 2003-03-27 IS IS6761A patent/IS6761A/is unknown
- 2003-04-15 NO NO20031737A patent/NO20031737L/no unknown
- 2003-04-17 EC EC2003004558A patent/ECSP034558A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2424729A1 (en) | 2002-04-25 |
| EA200300474A1 (ru) | 2003-10-30 |
| MXPA03003485A (es) | 2003-07-14 |
| WO2002032377A3 (en) | 2002-08-22 |
| WO2002032377A2 (en) | 2002-04-25 |
| PL361053A1 (en) | 2004-09-20 |
| BG107676A (bg) | 2003-11-28 |
| KR20030042020A (ko) | 2003-05-27 |
| ECSP034558A (es) | 2003-06-25 |
| BR0114689A (pt) | 2003-07-01 |
| JP2004511502A (ja) | 2004-04-15 |
| NO20031737D0 (no) | 2003-04-15 |
| AU2002232381B2 (en) | 2004-11-18 |
| CN1469743A (zh) | 2004-01-21 |
| EE200300153A (et) | 2003-06-16 |
| IS6761A (is) | 2003-03-27 |
| IL154984A0 (en) | 2003-10-31 |
| NO20031737L (no) | 2003-06-19 |
| SK4772003A3 (en) | 2003-08-05 |
| EP1333827A2 (en) | 2003-08-13 |
| AU3238102A (en) | 2002-04-29 |
| HUP0303563A2 (hu) | 2004-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20021083A1 (es) | Moduladores de los receptores estrogenos | |
| PE20060401A1 (es) | Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno | |
| CR8753A (es) | Derivados de tetraazabenzo [e] azuleno y sus analogos | |
| CY1106486T1 (el) | Μεθοδος παρασκευης 2-(κινοξαλιν-5-υλσουλφονυλαμινο) βενζαμιδικων ενωσεων | |
| PE69299A1 (es) | Compuestos calciliticos | |
| PE20030601A1 (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados | |
| ES2180981T3 (es) | Procedimiento para la preparacion de una sal de magnesio de un heterociclo de sulfinilo sustituido. | |
| PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
| PE20061084A1 (es) | Compuestos derivados de 2-ciano-3-(halo)alcoxi-bencenosulfonamida | |
| AR008861A1 (es) | COMPUESTOS DE LACTAMA E IMIDA HETEROCICLICOS DE ARALQUILO Y ARALQUILEDENO, COMPUESTOS INTERMEDIARIOS PARA SU SíNTESIS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN. | |
| NO20041504L (no) | Lactamderivater som antagonister for humane 11CBY reseptorer. | |
| EA200970326A1 (ru) | Алкильные производные в качестве метаботропных рецепторов глутамата | |
| PE20070108A1 (es) | Control de parasitos en animales con derivados de n-[(feniloxi)fenil]-1,1,1-trifluorometansulfonamida y de n-[(fenilsulfanil)fenil]-1,1,1-trifluorometansulfonamida | |
| UY28215A1 (es) | Quinazolinas utiles como moduladores de canales iónicos | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| PE20060610A1 (es) | Derivados tetraciclicos como moduladores de los receptores de estrogeno | |
| PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
| PE20060457A1 (es) | Derivados de difenil eter como antagonistas de los receptores 5ht2 | |
| DK1408961T3 (da) | 2 pyrrolidon-derivater som prostanoide agonister | |
| PA8576001A1 (es) | "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso". | |
| PE20060590A1 (es) | COMPUESTOS ESTEROIDALES 15ß-SUSTITUIDOS CON ACTIVIDAD SELECTIVA DEL RECEPTOR DE ESTROGENOS | |
| DE602006004882D1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
| PE20040678A1 (es) | Moduladores de los receptores selectivos de estrogenos | |
| DE60113032D1 (de) | Glucocorticoid Rezeptor Modulatoren | |
| DE60120077D1 (de) | Modulatoren des Glucocorticoid-Rezeptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |